Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- معلومة اضافية
- المصدر:
Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
- بيانات النشر:
Publication: 2002- : London : Nature Publishing Group on behalf of Cancer Research UK
Original Publication: London, Lewis.
- الموضوع:
- نبذة مختصرة :
Background: Tumours are responsive to temozolomide (TMZ) if they are deficient in O(6)-methylguanine-DNA methyltransferase (MGMT), and mismatch repair (MMR) proficient.
Methods: The effect of TMZ on medulloblastoma (MB) cell killing was analysed with clonogenic survival assays. Expression of DNA repair genes and enzymes was investigated using microarrays, western blot, and immunohistochemistry. DNA sequencing and promoter methylation analysis were employed to investigate the cause of loss of the expression of MMR gene MLH1.
Results: Temozolomide exhibited potent cytotoxic activity in D425Med (MGMT deficient, MLH1 proficient; IC(50)=1.7 μM), moderate activity against D341Med (MGMT proficient, MLH1 deficient), and DAOY MB cells (MGMT proficient, MLH1 proficient). MGMT inhibitor O(6)-benzylguanine sensitised DAOY, but not D341Med cells to TMZ. Of 12 MB cell lines, D341Med, D283Med, and 1580WÜ cells exhibited MMR deficiency due to MLH1 promoter hypermethylation. DNA sequencing of these cells provided no evidence for somatic genetic alterations in MLH1. Expression analyses of MMR and MGMT in MB revealed that all patient specimens (n=74; expression array, n=61; immunostaining, n=13) are most likely MMR proficient, whereas some tumours had low MGMT expression levels (according to expression array) or were totally MGMT deficient (3 out of 13 according to immunohistochemistry).
Conclusion: A subset of MB may respond to TMZ as some patient specimens are MGMT deficient, and tumours appear to be MMR proficient.
- References:
Genes Chromosomes Cancer. 2012 Jan;51(1):83-91. (PMID: 22034109)
Br J Cancer. 2010 Nov 9;103(10):1588-96. (PMID: 20978505)
Nucleic Acids Res. 2005 Aug 16;33(14):e128. (PMID: 16106041)
BMC Cancer. 2011 Feb 16;11:74. (PMID: 21324178)
Gastroenterology. 2005 May;128(5):1160-71. (PMID: 15887099)
Pediatr Blood Cancer. 2010 Dec 1;55(6):1066-71. (PMID: 20589656)
Acta Neuropathol. 2012 Apr;123(4):473-84. (PMID: 22358457)
DNA Repair (Amst). 2004 Nov 2;3(11):1389-407. (PMID: 15380096)
Oncology. 2010;78(2):103-14. (PMID: 20357518)
J Neuropathol Exp Neurol. 1985 Sep;44(5):472-85. (PMID: 2993532)
J Neurooncol. 2010 May;97(3):311-22. (PMID: 19841865)
Neuro Oncol. 2004 Jul;6(3):200-7. (PMID: 15279712)
Pediatr Blood Cancer. 2008 Mar;50(3):549-53. (PMID: 17941066)
Oncogene. 2009 Feb 12;28(6):899-909. (PMID: 19060925)
Pharmacol Res. 2007 Oct;56(4):275-87. (PMID: 17897837)
Cancer Res. 1994 Jun 15;54(12):3278-87. (PMID: 8205550)
Clin Cancer Res. 1998 Jun;4(6):1415-9. (PMID: 9626457)
Neuropathol Appl Neurobiol. 2008 Oct;34(5):547-54. (PMID: 18053027)
Clin Cancer Res. 2001 Mar;7(3):613-9. (PMID: 11297257)
Am J Pathol. 1988 Mar;130(3):472-84. (PMID: 3279793)
Neuro Oncol. 2009 Oct;11(5):458-67. (PMID: 19179424)
Cancer Res. 1990 Oct 1;50(19):6119-29. (PMID: 2205376)
PLoS One. 2008 Aug 28;3(8):e3088. (PMID: 18769486)
Am J Pathol. 2005 Apr;166(4):1153-62. (PMID: 15793295)
Cancer Res. 1990 Apr 15;50(8):2347-50. (PMID: 2180567)
Mol Cancer Ther. 2004 Sep;3(9):1127-35. (PMID: 15367707)
Clin Cancer Res. 2005 Apr 1;11(7):2747-55. (PMID: 15814657)
BMC Cancer. 2009 Jan 10;9:10. (PMID: 19134217)
Cancer Res. 2000 Oct 1;60(19):5464-9. (PMID: 11034089)
J Clin Oncol. 2002 May 1;20(9):2388-99. (PMID: 11981013)
Cancer Res. 1996 Dec 1;56(23):5375-9. (PMID: 8968088)
Cancer Res. 1995 Jul 1;55(13):2853-7. (PMID: 7796412)
Cancer. 2007 Jun 1;109(11):2349-56. (PMID: 17440981)
Br J Cancer. 2009 Jul 7;101(1):124-31. (PMID: 19536096)
Clin Cancer Res. 2001 Aug;7(8):2425-33. (PMID: 11489822)
Acta Neuropathol. 2012 Apr;123(4):465-72. (PMID: 22134537)
Cancer Res. 1993 Jul 15;53(14):3416-20. (PMID: 8324751)
Nature. 1998 Dec 17;396(6712):643-9. (PMID: 9872311)
Neurogenetics. 2006 May;7(2):67-80. (PMID: 16572319)
Nat Clin Pract Oncol. 2007 Feb;4(2):130-4. (PMID: 17259933)
Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6850-5. (PMID: 10359802)
Mol Cancer Ther. 2002 Jul;1(9):727-36. (PMID: 12479369)
Oncol Res. 1995;7(10-11):493-503. (PMID: 8866661)
Cancer. 2007 Oct 1;110(7):1542-50. (PMID: 17705175)
Clin Cancer Res. 2007 Apr 1;13(7):2038-45. (PMID: 17404084)
Int J Cancer. 2009 May 15;124(10):2333-40. (PMID: 19173287)
Neuro Oncol. 2002 Apr;4(2):75-85. (PMID: 11916498)
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6712-8. (PMID: 18006772)
Clin Cancer Res. 1997 Dec;3(12 Pt 1):2459-63. (PMID: 9815647)
N Engl J Med. 2005 Mar 10;352(10):987-96. (PMID: 15758009)
J Neurooncol. 2011 May;103(1):59-69. (PMID: 20820873)
Oncol Rep. 2009 Oct;22(4):773-9. (PMID: 19724855)
J Neuropathol Exp Neurol. 1985 Nov;44(6):592-605. (PMID: 4056828)
Br J Cancer. 2003 Feb 10;88(3):413-9. (PMID: 12569385)
- الرقم المعرف:
0 (Adaptor Proteins, Signal Transducing)
0 (Antineoplastic Agents, Alkylating)
0 (MLH1 protein, human)
0 (Nuclear Proteins)
0 (Tumor Suppressor Proteins)
7GR28W0FJI (Dacarbazine)
EC 2.1.1.- (DNA Modification Methylases)
EC 2.1.1.63 (MGMT protein, human)
EC 2.1.1.63 (O(6)-Methylguanine-DNA Methyltransferase)
EC 3.6.1.3 (MutL Protein Homolog 1)
EC 6.5.1.- (DNA Repair Enzymes)
YF1K15M17Y (Temozolomide)
- الموضوع:
Date Created: 20120915 Date Completed: 20121211 Latest Revision: 20211021
- الموضوع:
20221213
- الرقم المعرف:
PMC3494444
- الرقم المعرف:
10.1038/bjc.2012.403
- الرقم المعرف:
22976800
No Comments.